NASDAQ:ACRS - Aclaris Therapeutics Stock Price, Forecast & News

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics Inc (NASDAQ:ACRS) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.34) EPS for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.80. The biotechnology company earned $0.98 million during the quarter, compared to the consensus estimate of $5.87 million. Aclaris Therapeutics had a negative net margin of 1,165.39% and a negative return on equity of 83.22%. View Aclaris Therapeutics' Earnings History.

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Aclaris Therapeutics.

5 Wall Street analysts have issued 12 month price objectives for Aclaris Therapeutics' stock. Their forecasts range from $5.00 to $13.00. On average, they anticipate Aclaris Therapeutics' share price to reach $9.00 in the next year. This suggests a possible upside of 631.7% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.

News articles about ACRS stock have been trending extremely negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aclaris Therapeutics earned a news sentiment score of -4.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Aclaris Therapeutics.

Aclaris Therapeutics saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 3,410,000 shares, an increase of 11.4% from the January 30th total of 3,060,000 shares. Based on an average daily volume of 654,200 shares, the days-to-cover ratio is currently 5.2 days. Approximately 10.2% of the company's stock are sold short. View Aclaris Therapeutics' Current Options Chain.

Some companies that are related to Aclaris Therapeutics include Protagonist Therapeutics (PTGX), Geron (GERN), XOMA (XOMA), Kala Pharmaceuticals (KALA), Sol Gel Technologies (SLGL), Aeglea Bio Therapeutics (AGLE), Theratechnologies (THERF), Agile Therapeutics (AGRX), Arcturus Therapeutics (ARCT), LifeVantage (LFVN), MediciNova (MNOV), Abeona Therapeutics (ABEO), Genprex (GNPX), Nature's Sunshine Products (NATR) and Athersys (ATHX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), Abeona Therapeutics (ABEO), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Nabriva Therapeutics (NBRV), Progenics Pharmaceuticals (PGNX), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

Aclaris Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include MFN Partners Management LP (9.66%), Renaissance Technologies LLC (6.72%), EcoR1 Capital LLC (5.04%), Broadfin Capital LLC (4.56%), Man Group plc (3.13%) and Geode Capital Management LLC (1.40%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, James E Flynn, Kamil Ali-Jackson, Neal Walker and Stephen A Tullman. View Institutional Ownership Trends for Aclaris Therapeutics.

ACRS stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Alambic Investment Management L.P. and Virtu Financial LLC. View Insider Buying and Selling for Aclaris Therapeutics.

ACRS stock was bought by a variety of institutional investors in the last quarter, including MFN Partners Management LP, EcoR1 Capital LLC, Renaissance Technologies LLC, Broadfin Capital LLC, Parkman Healthcare Partners LLC, Jacobs Levy Equity Management Inc., Bank of New York Mellon Corp and Geode Capital Management LLC. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics.

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACRS stock can currently be purchased for approximately $1.23.

Aclaris Therapeutics has a market capitalization of $50.91 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.View Additional Information About Aclaris Therapeutics.

The official website for Aclaris Therapeutics is http://www.aclaristx.com/.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]